Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters

Kidney International

Volumn 92, Issue 1, 2017, Pages 26-36

  Ketteler, Markus ^a   Block, Geoffrey A ^b   Evenepoel, Pieter ^c   Fukagawa, Masafumi ^d   Herzog, Charles A ^e   McCann, Linda ^f   Moe, Sharon M ^g,h   Shroff, Rukshana ⁱ   Tonelli, Marcello A ^j   Toussaint, Nigel D ^k   Vervloet, Marc G ^l   Leonard, Mary B ^m  

^a KLINIKUM COBURG   (Germany)

^b Denver Nephrology   (United States)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e HENNEPIN COUNTY MEDICAL CENTER   (United States)

^f Eagle   (United States)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^j UNIVERSITY OF CALGARY   (Canada)

^k UNIVERSITY OF MELBOURNE   (Australia)

^l VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^m STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

bone mineral density; calcium; dialysis; hyperparathyroidism; hyperphosphatemia; KDIGO CKD MBD Guideline; kidney transplantation

Indexed keywords

ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; DOXERCALCIFEROL; GROWTH HORMONE; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE; PHOSPHATE BINDING AGENT; PLACEBO; VITAMIN D DERIVATIVE; BIOLOGICAL MARKER; CHELATING AGENT; PTH PROTEIN, HUMAN; VITAMIN D;

ARTICLE; BONE BIOPSY; BONE DENSITY; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; MEDICAL ASSESSMENT; OSTEOPOROSIS; PHOSPHATE BLOOD LEVEL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM; SENSITIVITY AND SPECIFICITY; BLOOD; BONE REMODELING; CONSENSUS; DIETARY SUPPLEMENT; DRUG EFFECTS; EVIDENCE BASED MEDICINE; NEPHROLOGY; RISK FACTOR; STANDARDS; TREATMENT OUTCOME;

BIOMARKERS; BONE REMODELING; CALCIUM; CHELATING AGENTS; CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER; CONSENSUS; DIETARY SUPPLEMENTS; EVIDENCE-BASED MEDICINE; HUMANS; NEPHROLOGY; PARATHYROID HORMONE; PHOSPHATES; RISK FACTORS; TREATMENT OUTCOME; VITAMIN D;

EID: 85021339948     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2017.04.006     Document Type: Article

References (4)

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD–MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD). Kidney Int Suppl(Suppl 113), 2009, S1–S130.
2. Ketteler, M., Elder, G.J., Evenepoel, P., et al. Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int 87 (2015), 502–528.
3. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 7 (2017), 1–59.
4. Guyatt, G., Oxman, A.D., Akl, E.A., et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64 (2011), 383–394.